Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

News Briefs

Hepatitis C Treatment May Halve Injections

November 6, 2002

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Early research indicates that Human Genome Sciences' experimental hepatitis C treatment, Albuferon-alpha, may require fewer doses and stay in the bloodstream longer than the treatments of its major competitors, the company said Monday. In a test involving 34 patients, researchers found that a single dose of Albuferon-alpha remains active in the bloodstream for up to 28 days, more than twice the duration of the leading treatments now on the market. The company contends the drug will require once or twice monthly injections, which could cut in half the number of annual injections for hepatitis C patients. The results, culled from the first stages of human tests, are by no means conclusive. About 3 million Americans are infected with hepatitis C, which can lie dormant for years before destroying the liver or triggering liver cancer.

Back to other CDC news for November 6, 2002

Previous Updates

Adapted from:
Washington Post
11.05.02; Michael Barbaro

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement